Indeed, anti-tumor necrosis factor-α (TNFα) antibodies have been successfully used in rheumatoid arthritis and in inflammatory bowel disease [3,4], while interleukin-1 (IL-1) inhibitors have found application in autoinflammatory diseases, such as Still’s disease, recurrent pericarditis, gout arthritis, Behçet’s disease, and a set of genetic conditions such as periodic fever [5]. This evidence concerns the gene TNF and rheumatoid arthritis.